Abstract 1201: Serum Corin Levels Predict Long Term Major Adverse Cardiovascular Events Post Percutaneous Coronary Intervention
Background: Corin is a Type II transmembrane protease responsible for the cleavage of Pro-Atrial Natriuretic Peptide (ANP) to ANP and Pro-Brain Natriuretic Peptide (BNP) to BNP.ANP and BNP have vasodilatory and antiproliferative functions, and may confer both paracrine and endocrine protective effect against atherosclerosis. In a previous study we found that serum corin levels are significantly lower in atherosclerotic patients (773 ± 21.9 SEM pg/ml, n=173), compared to healthy volunteers (1179 ± 58.8 pg/ml, n=95), p<0.0001.
Hypothesis: Plasma corin level measured pre-PCI (Percutaneous Coronary Intervention) can predict Major Adverse Cardiovascular Events (MACE) in long term follow up.
Methods and results: One hundred and nine patients with Acute Coronary Syndrome underwent successful PCI. Plasma corin levels were measured pre-PCI. The patients were followed up to three years, and long term MACE were recorded. Forty-nine patients suffered from MACE (mortality 6.1%, re-infarction 4.04%, angina pectoris 74.4%, recurrent revascularization 65.3%, CVA/TIA 10.2%). Plasma corin levels were significantly lower in the MACE group compared to the non-MACE group (729 pg/ml ±39, vs 849 pg/ml, ±45, p=0.05). BNP level showed no difference between the groups (91± 12.5ng/ml, and 99±19.7 ng/ml, p=0.733). Logistic regression analysis using corin as a continuous variable showed a significant prediction for MACE (p=0.007, OR= 0.998, 95%CI = 0.996 – 0.999, C-statistics = 0.634). By multivariate analysis corin was the only independent predictor of MACE p=0.015 while risk factors like diabetes mellitus p=0.379, hypertension, p=0.792, hyperlipidemia, p=0.665, and smoking, p=0.432 were non-significant.
Conclusion: Plasma corin level may be used as a predictor of long term MACE in patients post-PCI.